Thomas Rudolph, MD

Dr. Thomas Rudolph brings deep expertise in life sciences, pharmaceuticals, and private equity, with a distinguished career spanning more than two decades. Most recently, he was CEO of EHC N.V. and currently holds board and advisory roles in biotechnology and specialty pharma companies.

Before leaving McKinsey & Company as a Senior Partner in 2021, he advised leading pharmaceutical and specialty pharma companies in the U.S. and Europe. He founded the McKinsey Cancer Center and the European Healthcare Transactions team.

Dr. Rudolph holds a Medical Doctor degree from the University of Tuebingen Medical School, where his doctoral research focused on Molecular Biology and Oncology. He also earned a minor in Business Administration from the University of Tuebingen Business School.